You have 9 free searches left this month | for more free features.

T-cell Non-Hodgkin's lymphoma

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

T-cell Non-Hodgkin's Lymphoma Trial (CD147- CAR T cells)

Not yet recruiting
  • T-cell Non-Hodgkin's Lymphoma
  • CD147- CAR T cells
  • (no location specified)
Aug 1, 2022

T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma, Peripheral T-cell Lymphoma Trial in Chicago (Fenretinide)

Not yet recruiting
  • T-cell Lymphoma
  • +10 more
  • Chicago, Illinois
    Rush University Medical Center
Oct 24, 2022

Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mature T- and NK-Cell

Active, not recruiting
  • Recurrent Anaplastic Large Cell Lymphoma
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 30, 2023

Folliculotropic Mycosis Fungoides, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides Trial in United

Recruiting
  • Folliculotropic Mycosis Fungoides
  • +7 more
  • Durvalumab
  • +2 more
  • Duarte, California
  • +3 more
Jan 12, 2023

Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Grade 1

Active, not recruiting
  • Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
  • +18 more
  • Anti-ICOS Monoclonal Antibody MEDI-570
  • +2 more
  • Duarte, California
  • +22 more
Jan 18, 2023

T-cell Non-Hodgkin Lymphoma, Lymphoma, Extranodal NK-T-Cell Trial in Busan, Daegu (Busulfan, Fludarabine)

Recruiting
  • T-cell Non-Hodgkin Lymphoma
  • Lymphoma, Extranodal NK-T-Cell
  • Busan, Korea, Republic of
  • +1 more
Aug 17, 2022

Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Adult T-Cell

Recruiting
  • Recurrent Adult T-Cell Leukemia/Lymphoma
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Nov 18, 2022

Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral Trial (SGN-35T)

Not yet recruiting
  • Lymphoma, T-Cell, Cutaneous
  • +5 more
  • (no location specified)
Nov 2, 2023

Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin

Active, not recruiting
  • Adult Lymphocyte Depletion Hodgkin Lymphoma
  • +16 more
  • 6,8-bis(benzylthio)octanoic acid
  • bendamustine hydrochloride
  • Winston-Salem, North Carolina
  • +1 more
Apr 8, 2022

Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,

Not yet recruiting
  • Non-hodgkin Lymphoma
  • +9 more
  • CD79b-19 CAR T cells
  • +2 more
  • Boston, Massachusetts
    Massachusetts General Hospital
Sep 6, 2023

B-Cell Non Hodgkin Lymphoma, B-Cell Acute Lymphoblastic Leukemia Trial in Hanoi (anti-CD19 CAR T-cells)

Recruiting
  • B-Cell Non Hodgkin Lymphoma
  • B-Cell Acute Lymphoblastic Leukemia
  • anti-CD19 CAR T-cells
  • Hanoi, Vietnam
    Vinmec Research Institute of Stem Cell and Gene Technology
Sep 5, 2023

T-cell Non-Hodgkin Lymphoma Trial in Boston (Cyclophosphamide, Doxorubicin, Vincristine)

Terminated
  • T-cell Non-Hodgkin Lymphoma
  • Boston, Massachusetts
  • +1 more
Jan 26, 2023

Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Recurrent DLBCL Trial in Rochester (procedure, biological,

Active, not recruiting
  • Aggressive Non-Hodgkin Lymphoma
  • +9 more
  • Cryosurgery
  • +5 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Aug 9, 2022

Recurrent Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous

Recruiting
  • Recurrent Anaplastic Large Cell Lymphoma
  • +8 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Apr 6, 2022

(CHANT)Real World Study of Duvelisib in Treatment of

Not yet recruiting
  • Follicular Lymphoma
  • +5 more
  • (no location specified)
Jun 20, 2023

Leukemia, Acute Lymphoblastic, Lymphoma, Non-Hodgkin Trial in Ribeirao Preto (CART-19)

Not yet recruiting
  • Leukemia, Acute Lymphoblastic
  • Lymphoma, Non-Hodgkin
  • CART-19
  • Ribeirao Preto, Sao Paulo, Brazil
    Ribeirao Preto School of Medicine, University of Sao Paulo
Oct 23, 2023

T Cell Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma Trial in

Recruiting
  • T Cell Non-Hodgkin Lymphoma
  • +3 more
  • AUTO4
  • Barcelona, Spain
  • +4 more
Feb 1, 2022

Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Hepatosplenic T-Cell Lymphoma Trial

Completed
  • Anaplastic Large Cell Lymphoma, ALK-Negative
  • +9 more
  • Autologous Hematopoietic Stem Cell Transplantation
  • +8 more
  • Duarte, California
  • +7 more
Nov 4, 2022

Non Hodgkin's Lymphoma Trial in Beijing (TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T),

Not yet recruiting
  • Non Hodgkin's Lymphoma
  • TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T)
  • +2 more
  • Beijing, China
  • +2 more
Aug 23, 2023

T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Angioimmunoblastic T-cell Lymphoma Trial in Saint Louis (WU-CART-007)

Not yet recruiting
  • T-Cell Non-Hodgkin Lymphoma
  • +14 more
  • WU-CART-007
  • Saint Louis, Missouri
    Washington University School of Medicine
Jan 17, 2023

Lymphoma, Non-Hodgkin Trial (JNJ-87801493, JNJ-80948543, JNJ-75348780)

Not yet recruiting
  • Lymphoma, Non-Hodgkin
  • (no location specified)
Nov 15, 2023

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Trial in Suzhou (Obinutuzumab, Zanubrutinib, Lenalidomide)

Enrolling by invitation
  • Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
  • Suzhou, Jiangsu, China
    the First Affiliated Hospital of Soochow University
Mar 22, 2023

Hematopoietic Cell Transplantation Recipient, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in

Active, not recruiting
  • Hematopoietic Cell Transplantation Recipient
  • +3 more
  • Allogeneic Bone Marrow Transplantation
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 18, 2022

Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Diffuse Large B Cell Lymphoma
  • CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
  • Tianjin, Tianjin, China
    Tianjin Cancer Hospital
Nov 19, 2023

Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory Trial in Columbus

Not yet recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +5 more
  • CD19 specific Chimeric Antigen Receptor T Cell
  • Columbus, Ohio
    Nationwide Children's Hospital
Mar 9, 2023